Attitudes of European Geneticists Regarding Expanded Carrier Screening

Abstract

ObjectiveTo explore attitudes of clinical and molecular geneticists about the implementation of multi-disease or expanded carrier screening (ECS) for monogenic recessive disorders. DesignQualitative; semistructured interviews. SettingIn person or via Skype. Interviews were audiorecorded and transcribed verbatim. ParticipantsEuropean clinical and molecular geneticists with expertise in carrier screening (N = 16). MethodsInductive content analysis was used to identify common content categories in the data. ResultsParticipants recognized important benefits of ECS, but they also identified major challenges, including limited benefit of ECS for most couples in the general population, lack of knowledge on carrier screening among nongenetic health care providers and the general public, potential negative implications of ECS for society, and limited economic resources. Participants favored an evidence-based approach to the implementation of population-wide ECS and were reluctant to actively offer ECS in the absence of demonstrable benefits. However, there was a consensus among the participants that ECS should be made available to couples who request the test. In addition, they believed ECS could be routinely offered to all people who use assisted reproduction. ConclusionAlthough a limited ECS offer is practical, it also raises concerns over equality in access to screening. A comprehensive risk–benefit analysis is needed to determine the desirability of systematic population-wide ECS.